426 related articles for article (PubMed ID: 27069085)
1. Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.
Reeder-Hayes K; Peacock Hinton S; Meng K; Carey LA; Dusetzina SB
J Clin Oncol; 2016 Jun; 34(17):2003-9. PubMed ID: 27069085
[TBL] [Abstract][Full Text] [Related]
2. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network.
Freedman RA; Hughes ME; Ottesen RA; Weeks JC; He Y; Wong YN; Theriault R; Keating NL
Cancer; 2013 Feb; 119(4):839-46. PubMed ID: 23011924
[TBL] [Abstract][Full Text] [Related]
3. Socioeconomic disparities in breast cancer treatment among older women.
White A; Richardson LC; Krontiras H; Pisu M
J Womens Health (Larchmt); 2014 Apr; 23(4):335-41. PubMed ID: 24350590
[TBL] [Abstract][Full Text] [Related]
4. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
Chen L; Li CI
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
[TBL] [Abstract][Full Text] [Related]
5. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.
Vaz-Luis I; Lin NU; Keating NL; Barry WT; Lii J; Burstein HJ; Winer EP; Freedman RA
Breast Cancer Res Treat; 2016 Aug; 159(1):151-62. PubMed ID: 27484879
[TBL] [Abstract][Full Text] [Related]
6. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
[TBL] [Abstract][Full Text] [Related]
7. Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery?
Keating NL; Kouri E; He Y; Weeks JC; Winer EP
Med Care; 2009 Jul; 47(7):765-73. PubMed ID: 19536008
[TBL] [Abstract][Full Text] [Related]
8. Racial and Socioeconomic Disparities in Cardiotoxicity Among Women With HER2-Positive Breast Cancer.
Al-Sadawi M; Hussain Y; Copeland-Halperin RS; Tobin JN; Moskowitz CS; Dang CT; Liu JE; Steingart RM; Johnson MN; Yu AF
Am J Cardiol; 2021 May; 147():116-121. PubMed ID: 33617819
[TBL] [Abstract][Full Text] [Related]
9. Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer.
Sail K; Franzini L; Lairson D; Du X
Ethn Health; 2012; 17(3):309-23. PubMed ID: 22066691
[TBL] [Abstract][Full Text] [Related]
10. Race and sex differences in the receipt of timely and appropriate lung cancer treatment.
Shugarman LR; Mack K; Sorbero ME; Tian H; Jain AK; Ashwood JS; Asch SM
Med Care; 2009 Jul; 47(7):774-81. PubMed ID: 19536007
[TBL] [Abstract][Full Text] [Related]
11. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
12. Racial Differences in Treatment and Survival among Veterans and Non-Veterans with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations.
Williams CD; Alpert N; Redding TS; Bullard AJ; Flores RM; Kelley MJ; Taioli E
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):112-118. PubMed ID: 31624076
[TBL] [Abstract][Full Text] [Related]
13. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
14. Residual treatment disparities after oncology referral for rectal cancer.
Morris AM; Billingsley KG; Hayanga AJ; Matthews B; Baldwin LM; Birkmeyer JD
J Natl Cancer Inst; 2008 May; 100(10):738-44. PubMed ID: 18477800
[TBL] [Abstract][Full Text] [Related]
15. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
16. Disparities in Breast Cancer Survival by Socioeconomic Status Despite Medicare and Medicaid Insurance.
Silber JH; Rosenbaum PR; Ross RN; Reiter JG; Niknam BA; Hill AS; Bongiorno DM; Shah SA; Hochman LL; Even-Shoshan O; Fox KR
Milbank Q; 2018 Dec; 96(4):706-754. PubMed ID: 30537364
[TBL] [Abstract][Full Text] [Related]
17. Racial disparities in the development of breast cancer metastases among older women: a multilevel study.
Schootman M; Jeffe DB; Gillanders WE; Aft R
Cancer; 2009 Feb; 115(4):731-40. PubMed ID: 19130463
[TBL] [Abstract][Full Text] [Related]
18. Racial disparities in treatment and survival of male breast cancer.
Crew KD; Neugut AI; Wang X; Jacobson JS; Grann VR; Raptis G; Hershman DL
J Clin Oncol; 2007 Mar; 25(9):1089-98. PubMed ID: 17369572
[TBL] [Abstract][Full Text] [Related]
19. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006.
Fedewa SA; Ward EM; Stewart AK; Edge SB
J Clin Oncol; 2010 Sep; 28(27):4135-41. PubMed ID: 20697082
[TBL] [Abstract][Full Text] [Related]
20. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
